@article{a3a337f25d6f44e8bff3fe4fb2df9d7c,
title = "Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies",
abstract = "Dementia with Lewy bodies (DLB) is characterized by preserved whole brain and medial temporal lobe volumes compared with Alzheimer's disease dementia (AD) on magnetic resonance imaging. However, frequently coexistent AD-type pathology may influence the pattern of regional brain atrophy rates in DLB patients. We investigated the pattern and magnitude of the atrophy rates from 2 serial MRIs in autopsy-confirmed DLB patients (n = 20) and mixed DLB/AD patients (n = 22), compared with AD (n = 30) and elderly nondemented control subjects (n = 15), followed antemortem. DLB patients without significant AD-type pathology were characterized by lower global and regional rates of atrophy, similar to control subjects. The mixed DLB/AD patients displayed greater atrophy rates in the whole brain, temporoparietal cortices, hippocampus and amygdala, and ventricle expansion, similar to AD patients. In the DLB and DLB/AD patients, the atrophy rates correlated with Braak neurofibrillary tangle stage, cognitive decline, and progression of motor symptoms. Global and regional atrophy rates are associated with AD-type pathology in DLB, and these rates can be used as biomarkers of AD progression in patients with LB pathology.",
keywords = "Alzheimer's disease, Atrophy rate, Autopsy-confirmed dementia with Lewy bodies, Braak neurofibrillary tangle stage, Sample size estimate, Serial MRI",
author = "Zuzana Nedelska and Ferman, {Tanis J.} and Boeve, {Bradley F.} and Przybelski, {Scott A.} and Lesnick, {Timothy G.} and Murray, {Melissa E.} and Gunter, {Jeffrey L.} and Senjem, {Matthew L.} and Prashanti Vemuri and Smith, {Glenn E.} and Geda, {Yonas E.} and Jonathan Graff-Radford and Knopman, {David S.} and Petersen, {Ronald C.} and Parisi, {Joseph E.} and Dickson, {Dennis W.} and Jack, {Clifford R.} and Kejal Kantarci",
note = "Funding Information: The study was funded by the National Institutes of Health P50-AG16574/P1 and R01AG040042 (to Kejal Kantarci), R01-AG015866 (to Tanis J. Ferman), R01-AG11378 (to Clifford R. Jack), and P50-AG16574 (to Ronald C. Petersen), Mangurian Foundation , and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program. Zuzana Nedelska is supported by the CTSA grant number UL1 TR000135 from the National Center for Advancing Translational Sciences, United States , a component of the NIH (its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH), Grant Agency of Charles University in Prague (doctoral student grant 624012 ), and European Regional Development Fund–Project FNUSA-ICRC CZ.1.05/1.1.00/02.0123, European Social Fund within the project Young Talent Incubator II (reg. CZ.1.07/2.3.00/20.0117) and the State Budget of the Czech Republic . Funding Information: Dr Nedelska, Mr. Przybelski, Mr. Lesnick, Dr Gunter, Dr Senjem, Dr Graff-Radford, and Dr Geda report no disclosures. Dr Ferman is funded by the NIH (Mayo Clinic Alzheimer's Disease Research Center/Project 1- P50-AG16574 /P1 [Co-I]). Dr Boeve has served as an investigator for a clinical trial sponsored by Cephalon . He has received honoraria from the American Academy of Neurology. He receives research support from the National Institute on Aging ( P50-AG16574 [Co-I], U01 AG06786 [Co-I], R01-AG15866 [Co-I], and U24-AG26395 [Co-I]) and the Alzheimer's Association ( IIRG-05–14,560 [PI]). Dr Murray is funded by P50-NS72187-03 (Co-I) and Robert H. and Clarice Smith and Abigail van Buren Alzheimer Disease Research Fellowship. Dr Vemuri is funded by NIH R00-AG37573 . Dr Knopman serves as Deputy Editor for Neurology; served on a Data Safety Monitoring Board for Lilly Pharmaceuticals; served as a consultant to TauRx, was an investigator in clinical trials sponsored by Baxter , Elan Pharmaceuticals , and Forest Pharmaceuticals for the past 2 years; and receives research support from the NIH . Dr Smith is funded by the NIH ( P50-AG16574 ). Dr Parisi receives publishing royalties for Principles & Practice of Neuropathology, 2nd edition. Dr Petersen serves on scientific advisory boards for Elan Pharmaceuticals, Wyeth Pharmaceuticals, and GE Healthcare and receives research support from the NIH ( P50-AG16574 [PI] and U01-AG06786 [PI], R01-AG11378 [Co-I], and U01–24904 [Co-I]). Dr Dickson is funded by the NIH ( P50-AG16574 /Neuropathology Core [PI], P01AG017216 [PI], P50-NS072187 [PI], and R01-AG040042 [Co-I]). Dr Jack serves as a consultant for Janssen, Bristol-Meyer-Squibb, General Electric, Siemens, and Johnson and Johnson and is involved in clinical trials sponsored by Allon and Baxter, Inc . He receives research funding from the National Institutes of Health ( R01-AG011378 , RO1-AG037551 , U01-HL096917 , U01-AG032438 , and U01-AG024904 ), and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation Family. Dr Kantarci serves on the data safety monitoring board for Pfizer Inc and Takeda Global Research & Development Center, Inc; and she is funded by the NIH ( R01AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], and R01 AG11378 [Co-I]). Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",
year = "2015",
month = jan,
day = "1",
doi = "10.1016/j.neurobiolaging.2014.07.005",
language = "English (US)",
volume = "36",
pages = "452--461",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "1",
}